Analytical Data
-
Gene name
HBG1
- Application
-
Alternative Names
Gamma-1-globin (Hb F Agamma) (Hemoglobin gamma-1 chain) (Hemoglobin gamma-A chain)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P69891
-
Expression Region
2-147aa
-
Molecular Weight
23.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on HBG1 recombinant protein is rooted in the need to understand and manipulate fetal hemoglobin (HbF) synthesis for therapeutic applications in hemoglobinopathies such as sickle cell disease and beta-thalassemia. HBG1, or the gene encoding gamma globin, plays a crucial role in the production of HbF, which is characterized by its ability to mitigate the pathological effects associated with abnormal adult hemoglobin variants. Typically, HbF levels are diminished in patients with sickle cell disease, leading to severe clinical manifestations. By investigating the recombinant expression of HBG1, researchers aim to elucidate the regulatory mechanisms governing gamma globin expression and to leverage this knowledge for the development of innovative gene therapies. Techniques such as gene editing, small molecule modulators, and the exploration of epigenetic changes are being employed to enhance HBG1 expression, thereby promoting HbF levels in patients. Furthermore, the use of recombinant HBG1 allows for detailed structural and functional analyses, facilitating the design of drugs that could reactivate gamma globin synthesis. The ultimate goal of this research is to provide new avenues for treating hemoglobin disorders, improving patient outcomes, and contributing to a greater understanding of hemoglobin biology.
